Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutic (NQ: UTHR )

276.77 +1.58 (+0.57%)
Streaming Delayed Price Updated: 9:47 AM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,599
Open 274.55
Bid (Size) 275.94 (4)
Ask (Size) 277.64 (4)
Prev. Close 275.19
Today's Range 273.52 - 276.77
52wk Range 208.62 - 279.98
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Ratings For United Therapeutics
Via Benzinga
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. 
Via InvestorPlace

Performance

YTD
+21.74%
+21.74%
1 Month
+18.25%
+18.25%
3 Month
+29.24%
+29.24%
6 Month
+20.11%
+20.11%
1 Year
+20.55%
+20.55%

More News

Read More
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
Via Investor's Business Daily
NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
Via Investor's Business Daily
3 Biotech Stocks to Double Your Money in the Next 24 Months
Via InvestorPlace
The Latest Analyst Ratings For United Therapeutics
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss United Therapeutics Stock
Via Benzinga
Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity
Via Benzinga
UTHR Stock Earnings: United Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
CORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
From United Therapeutics Corporation
Via Business Wire
NASDAQ:UTHR stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
From United Therapeutics Corporation
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation
From United Therapeutics Corporation
Via Business Wire
The Bargain Hunter’s Portfolio: 7 Smart Stock Buys for the Shrewd Investor
Via InvestorPlace
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
From United Therapeutics Corporation
Via Business Wire
The 3 Most Undervalued Nasdaq Stocks to Buy in March 2024
Via InvestorPlace
Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making
Via InvestorPlace
United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference
From United Therapeutics Corporation
Via Business Wire
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.